INVESTIGADORES
BALERIO Graciela Noemi
artículos
Título:
Ability of baclofen to prevent somatic manifestations and neurochemical changes during nicotine withdrawal
Autor/es:
ANDRÉS P VARANI; LIRANE MACHADO MOUTINHO; MARIELA CALVO; GRACIELA N. BALERIO
Revista:
DRUG AND ALCOHOL DEPENDENCE
Editorial:
ELSEVIER IRELAND LTD
Referencias:
Año: 2011 vol. 119 p. 5 - 12
ISSN:
0376-8716
Resumen:
Background: Nicotine (NIC), the major active component of tobacco, is critical in the maintenance ofthe smoking habit. The aims of the present study were to analyze the behavioural and neurochemicalvariations during NIC withdrawal syndrome in mice, and whether they are prevented with baclofen (BAC,GABAB receptor agonist).Methods: Swiss-Webster albino mice received NIC (2.5 mg/kg, s.c.) 4 times daily, for 7 consecutive days.On day 8 (the day of the experiment), NIC-treated mice received the nicotine antagonist mecamylamine(MEC, 2 mg/kg, i.p.) 1 h after the last dose of NIC. A second group of dependent mice received BAC (2 mg/kg,i.p.) before MEC-precipitated abstinence. The somatic signs were measured for 30 min. Dopamine (DA),serotonin (5-hydroxytryptamine; 5-HT) and its metabolites concentrations were determined by HPLC inthe striatum, cortex and hippocampus.Results: The global score was greater in the abstinent group compared to the control group. Moreover,the global score time course showed a higher increase at 10 min compared to the global score at 5 minor 30 min after MEC-precipitated NIC withdrawal. In addition, the global score was attenuated by BAC.The DA and dihydroxyphenyl acetic acid (DOPAC) cortical levels decreased in the abstinent group, whileBAC reestablished these levels 10 min after NIC withdrawal. Furthermore, DA and 5-HT striatal levelsdecreased during NIC withdrawal, and BAC reverted this decrease.Conclusion: In conclusion, the prevention of NIC withdrawal signs by BAC could be related to changes indopaminergic and serotonergic activity.
